Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

132 citing papers in PubMed.

1. Analysis of the TCRβ repertoire characteristics when combining radiotherapy and immunotherapy in cancer.Oncology letters · 2026
   Article
2. Advances in Targeted and Immunotherapy for High-Risk Cutaneous Malignancies.Oncology research · 2026
   Review
3. Effect of immune-related intratumoral microbiota and host gene expression on cancer prognosis.mSystems · 2025
   Article
4. Biological mechanism and immune response of MHC-II expression in tumor cells.Cancer biology & medicine · 2025
   Review
5. Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose.The Journal of clinical investigation · 2025
   Observational
6. Combination Immunotherapy for Mucosal Melanoma: Molecular Mechanism, Research Status, and Future Directions.Current treatment options in oncology · 2025
   Review
7. Personalization of Radiotherapy Dose in HPV Positive Oropharynx Cancer Using GARD.medRxiv : the preprint server for health sciences · 2025
   Article
8. Predictive value of NUF2 for prognosis and immunotherapy responses in pan-cancer.Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
   Article
9. Multi-cohort validation based on a novel prognostic signature of anoikis for predicting prognosis and immunotherapy response of esophageal squamous cell carcinoma.Frontiers in oncology · 2025
   Article
10. Comprehensive analysis of palmitoylation-related proteins for prognostic risk evaluation and tumor immune microenvironment assessment in glioma.Frontiers in immunology · 2025
    Article
11. Multi-cohort validation based on coagulation-related genes for predicting prognosis of esophageal squamous cell carcinoma.Frontiers in immunology · 2025
    Article
12. Multi‑cohort Validation Based on Disulfidptosis-Related lncRNAs for Predicting Prognosis and Immunotherapy Response of Esophageal Squamous Cell Carcinoma.OncoTargets and therapy · 2025
    Article
13. Necroptosis-related lncRNAs: biomarkers for predicting prognosis and immune response in lung adenocarcinoma.Translational lung cancer research · 2024
    Article
14. Ten challenges and opportunities in computational immuno-oncology.Journal for immunotherapy of cancer · 2024
    Review
15. Pan-cancer analysis of m1A writer gene RRP8: implications for immune infiltration and prognosis in human cancers.Discover oncology · 2024
    Article
16. CD24 affects the immunosuppressive effect of tumor-infiltrating cells and tumor resistance in a variety of cancers.Discover oncology · 2024
    Article
17. Integrating Machine Learning and Mendelian Randomization Determined a Functional Neurotrophin-Related Gene Signature in Patients with Lower-Grade Glioma.Molecular biotechnology · 2024
    Article
18. A new perspective: deciphering the aberrance and clinical implication of disulfidptosis signatures in clear cell renal cell carcinoma.Aging · 2024
    Article
19. Prognostic and therapeutic roles ofAging · 2024
    Article
20. Tumour mutation burden and infiltrating immune cell subtypes influenced the breast cancer prognosis.Translational cancer research · 2024
    Article

72 more citing papers are in PubMed but not listed here.

Corrections and comments

• Comment on
  Genetic basis for clinical response to CTLA-4 blockade in melanoma.2014

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as